{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-035032","form_type":"8-K","ticker":"SDEV","cik":"0001389545","company_name":"Stablecoin Development Corp","filed_at":"2023-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.833832+00:00","generated_at":"2026-06-07T08:55:14.640748+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NovaBay reprices Series B warrants to $0.25, raises ~$554K; anti-dilution adds 23.4M shares","bullets":["Exercise price reduced from $1.30 to $0.25; initial exercise of 2.2M shares nets ~$555K gross proceeds.","New Series C warrants issued for 100% of exercised shares, exercisable at $0.25 after stockholder approval.","Anti-dilution adjustments to Series B/C preferred stock lower conversion price to $0.25, adding ~23.4M potential common shares.","Holders may exercise remaining warrants at $0.25 through Jan 26, 2024; unexercised warrants revert to $1.30."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-035032","json":"https://secwatch.observer/filing/0001437749-23-035032.json","markdown":"https://secwatch.observer/filing/0001437749-23-035032.md","text":"https://secwatch.observer/filing/0001437749-23-035032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1389545/000143774923035032/0001437749-23-035032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1389545/000143774923035032/nby20231218_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T08:55:14.640748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a1568325e7d47609366e43b77ab52a541e373dd9","claim":"Stablecoin Development Corp entered into Letter Agreements with existing holders of Series B-1 warrants and Series B-2 warrants valued at Issuance of new Series C Common Stock purchase warrants; anti-dilution adjustment triggered (effective 2023-12-21).","evidence_excerpt":"On December 21, 2023, NovaBay Pharmaceuticals, Inc. (the “ Company ”) announced that on December 21, 2023, it entered into letter agreements (the “ Letter Agreements ”) with certain of existing holders of its Series B-1 warrants (the “ Series B-1 Warrants ”) to purchase Company common stock, par value $0.01 per share (“ Common Stock ”) and its the Series B-2 warrants (the “ Series B-2 Warrants ” and together with the Series B-1 Warrants, the “ Series B Warrants ”) to purchase Common Stock that were issued to such holders pursuant to a Securities Purchase Agreement, dated April 27, 2023.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1389545/000143774923035032/0001437749-23-035032-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"existing holders of Series B-1 warrants and Series B-2 warrants"},{"label":"Value","value":"Issuance of new Series C Common Stock purchase warrants; anti-dilution adjustment triggered"},{"label":"Effective","value":"2023-12-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}